Creative Planning Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Creative Planning bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 20,947 shares of the biopharmaceutical company’s stock, valued at approximately $182,000.

Several other hedge funds also recently bought and sold shares of the company. Atlas Capital Advisors LLC purchased a new stake in shares of Ocular Therapeutix during the 2nd quarter valued at about $34,000. Amalgamated Bank boosted its stake in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,481 shares in the last quarter. Algert Global LLC bought a new position in shares of Ocular Therapeutix during the second quarter valued at approximately $69,000. Bayesian Capital Management LP acquired a new stake in Ocular Therapeutix in the first quarter valued at approximately $94,000. Finally, Ameritas Investment Partners Inc. boosted its stake in Ocular Therapeutix by 39.4% in the first quarter. Ameritas Investment Partners Inc. now owns 11,531 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,257 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on OCUL. Robert W. Baird decreased their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Scotiabank initiated coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Ocular Therapeutix Price Performance

Shares of OCUL stock opened at $10.96 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 16.64 and a quick ratio of 16.55. The firm’s 50-day moving average is $9.70 and its two-hundred day moving average is $7.85. Ocular Therapeutix, Inc. has a 12 month low of $2.02 and a 12 month high of $11.77. The company has a market capitalization of $1.71 billion, a PE ratio of -8.12 and a beta of 1.26.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.